Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Syenza News — health technology assessment, market access and health economics

Syenza's Top Picks

Latest News

Canal-side street in a northern European city with a stone bridge, cyclists and a glass office building

Cardiovascular And Metabolic Diseases

CHMP November 2026 Recommends Seven New Medicines for Approval

EMA’s CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.

Syenza TeamRead ›
Pharmacy counter with a dish of white tablets and a glass of water beside a window onto a town street

Cardiovascular And Metabolic Diseases

Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet

The CHMP recommended granting a marketing authorisation for AstraZeneca’s Baxfendy (baxdrostat) for insufficiently controlled hypertension. The European Commission makes the final decision. #SyenzaNews #MarketAccess

Syenza TeamRead ›
NHLS Governance Crisis Reaches Parliament With R1.8 Billion in Irregular Spending

Healthcare Spending Free account

NHLS Governance Crisis Reaches Parliament With R1.8 Billion in Irregular Spending

The NHLS governance crisis reached Parliament with R1.8 billion in irregular spending, an interim board and a disputed IP Capital consultancy.

Syenza TeamRead ›
Two brass balance scales on a wooden table beside a stethoscope

Clinical Guidelines And Protocols

Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024

Only 58% of EMA-approved drug indications from 2011 to 2024 had at least one trial population tested against an appropriate comparator. The share fell from 78% of 2011 to 2012 approvals to 39% of 2023 to 2024 approvals. #SyenzaNews #MarketAccess

Syenza TeamRead ›
prostate cancer screening guideline

Clinical Guidelines And Protocols

ACS Updates Prostate Cancer Screening Guideline for PSA Testing

“The American Cancer Society has updated its prostate cancer screening guideline, with regular PSA testing for average-risk men aged 50 to 69.” #SyenzaNews #ProstateCancer

Syenza TeamRead ›
SADC pharmaceutical pooled procurement

Health Policy

SADC Pharmaceutical Pooled Procurement Charter Signed in Durban

The Charter establishing the SADC Pharmaceuticals Pooled Procurement Services was signed in Durban on 12 November 2026, with Tanzania the first Member State to sign. #SyenzaNews #MarketAccess

Syenza TeamRead ›
Clean laboratory workbench with glass vials and a pharmacist in a white coat

Clinical Practice

Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa

Aspen Pharmacare has received approval for generic semaglutide in Brazil and South Africa, following Canada in July. Launches in all three markets are expected over the coming months. #SyenzaNews #MarketAccess

Syenza TeamRead ›
Villagers in a sunlit European town square beside a market stall of boxes and a balanced pair of brass scales

Drug Pricing

US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%

A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.

Syenza TeamRead ›
The EU HTA Regulation offers Latin American agencies lessons on shared clinical evidence, comparators and national decis

Cost Effectiveness Analysis

The EU HTA Regulation: What Latin America Can Learn

A PAHO, RedETSA and HTAi webinar on the EU HTA Regulation: what Latin American agencies can reuse from joint clinical assessments, and which elements may be hard to adapt.

Syenza TeamRead ›
artificial intelligence in medicine regulation

Artificial Intelligence And Machine Learning

Artificial Intelligence in Medicine Regulation: From Concept to Practice

EMA says it is moving artificial intelligence in medicine regulation from concept to practice. Its timeline runs from a 2021 joint workshop to research priorities published in August 2026. #SyenzaNews #MarketAccess #drugregulation

Syenza TeamRead ›

Value Science Weekly

The week in health technology assessment, market access and health economics — what moved, and what it means.

You can unsubscribe at any time. Read our privacy policy.

About this newsletter →

Search Intelligence